Clinical Trial Update: Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sirolimus plus tacrolimus for graft-versus-host disease prophylaxis after related stem cell transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Hematologic Malignancies
• Hodgkin Lymphoma
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma

Drugs mentioned

• Sirolimus (Sirolimus)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Hematologic Malignancies, Myelogenous Leukemia | Phase 2 | Status: COMPLETED